Akebia Therapeutics

305 articles with Akebia Therapeutics

• Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - July 02, 2020

  7/2/2020

  Akebia Therapeutics®, Inc. granted six newly-hired employees options to purchase an aggregate of 320,000 shares of Akebia's common stock on June 30, 2020, including an option to purchase 280,000 shares granted to David Spellman, Akebia's newly-hired Senior Vice President, Chief Financial Officer.

• Akebia Therapeutics Announces Approval of Vadadustat in Japan for the Treatment of Anemia Due to Chronic Kidney Disease in Dialysis-Dependent and Non-Dialysis Dependent Adult Patients

  6/29/2020

  Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the first regulatory approval of vadad

• Akebia Therapeutics Launches AkebiaShares, a Peer-to-Peer Educational Program Series for the Renal Community

  6/22/2020

  First Virtual Panel Features Renal Health Care Professionals Sharing Best Practices for Chronic Kidney Disease Patient Care in the COVID-19 Environment

• Akebia Therapeutics Announces New Chief Financial Officer

  6/18/2020

  Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose of bettering the lives of people impacted by kidney disease, today announced David A. Spellman is joining Akebia as its new Senior Vice President, Chief Financial Officer and Treasurer, effective June 29, 2020.

• Akebia Therapeutics Announces Data on Different Dosing Regimens of Ferric Citrate for Iron Deficiency Anemia Presented at 57th ERA-EDTA Virtual Congress

  6/10/2020

  Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that data from an investigational clinical research study on different dose regimens of ferric citrate for the treatment of iron deficiency anemia was presented at the 57

• Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 02, 2020

  6/2/2020

  Akebia Therapeutics, Inc., a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted three newly-hired employees options to purchase an aggregate of 72,000 shares of Akebia's common stock on May 29, 2020, as inducements material to each such employee's entering into employment with Akebia.

• Akebia Therapeutics to Present at Jefferies Virtual Global Healthcare Conference

  5/26/2020

  Akebia Therapeutics, Inc., a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, announced that its President and Chief Executive Officer, John P. Butler, will participate in the Jefferies Virtual Global Healthcare Conference on Tuesday, June 2 at 8:00 a.m. ET.

• Akebia Therapeutics Announces Change to Virtual Annual Meeting of Stockholders

  5/21/2020

  Akebia Therapeutics, Inc.  (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that due to the public health impact of the novel coronavirus (COVID-19) outbreak and governmental restrictions limiting the number of people who may gather together, and to

• Akebia Therapeutics Announces Full Exercise of Underwriters' Option to Purchase Additional Shares

  5/19/2020

  Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the underwriters of its previously announced public offering, which closed on May 14, 2020

• Akebia Therapeutics Announces Collaboration Partner's Submission of Supplemental New Drug Application for Use of Riona® (ferric citrate hydrate) to Treat Adult Patients with Iron Deficiency Anemia in Japan

  5/18/2020

  Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease, announced today that its collaboration partner, Japan Tobacco, Inc. (JT), has filed a supplemental New Drug Application (NDA) with the Pharmaceuticals and Medic

• Akebia Therapeutics Announces Pricing of Upsized Public Offering of Common Stock

  5/11/2020

  Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the pricing of an underwritten public offering of 11,000,000 shares of common stock at a public offering price of $12.00 per share.

• Akebia Therapeutics Announces Proposed Public Offering of Common Stock - May 11, 2020

  5/11/2020

  Akebia Therapeutics, Inc., a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, announced the commencement of a proposed underwritten public offering of approximately $100,000,000 of shares of its common stock.

• Akebia Therapeutics to Present at RBC Capital Markets Global Healthcare Virtual Conference

  5/8/2020

  Akebia Therapeutics , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that its President and Chief Executive Officer, John P. Butler , will participate in the 2020 RBC Capital Markets Global Healthcare Virtual Conference on Wednesday, May 20

• Akebia Announced Positive Top-Line Results from Global Phase 3 Program of Vadadustat for Treatment of Anemia Due to Chronic Kidney Disease in Adult Patients on Dialysis; Reports First Quarter 2020 Financial Results

  5/5/2020

  Akebia Therapeutics, Inc., announced positive top-line results from INNO2VATE, its global Phase 3 cardiovascular outcomes program evaluating the efficacy and safety of vadadustat, its investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor, versus darbepoetin alfa for the treatment of anemia due to chronic kidney disease in adult patients on dialysis.

• Vifor Pharma Announces Akebia’s Positive Top-Line Results From Global Phase-III Program of vadadustat for Treatment of Anaemia Due to Chronic Kidney Disease in Adult Dialysis-Dependent Patients

  5/5/2020

  Akebia’s vadadustat, an investigational oral HIF-PHI, achieves primary efficacy and cardiovascular safety endpoints

• Akebia Therapeutics Announces Positive Top-Line Results from Global Phase 3 Program of Vadadustat for Treatment of Anemia Due to Chronic Kidney Disease in Adult Patients on Dialysis

  5/5/2020

  Company to discuss top-line data on its scheduled first quarter financial results conference call today at 8:30 a.m. ET

• 

  Akebia Soars on Positive Phase III Data for Kidney Disease Drug

  5/5/2020

  Akebia Therapeutics’ investigational drug vadadustat hit the mark in the first of two Phase III trials in chronic kidney disease (CKD) patients who are on dialysis, and investors are pleased.

• Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 4, 2020

  5/4/2020

  Akebia Therapeutics, Inc., a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease, granted eight newly-hired employees options to purchase an aggregate of 95,300 shares of Akebia's common stock on April 30, 2020, as inducements material to each such employee's entering into employment with Akebia.

• Akebia Therapeutics to Report First Quarter 2020 Financial Results and Discuss Recent Business Highlights

  4/28/2020

  Akebia Therapeutics , Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease, today announced plans to release its financial results for the first quarter ended March 31, 2020 , on Tuesday, May 5, 2020 before the opening of

• Akebia Therapeutics Appoints Myles Wolf, M.D., M.M.Sc., Chief of Nephrology and Professor at Duke University School of Medicine, to Board of Directors

  4/7/2020

  Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease, today announced the appointment of Myles Wolf , M.D., M.M.Sc., to its Board of Directors, effective April 6 . Dr. Wolf is a leading clinical nephrologist a